PNS75 The Evolution of Payer Perceptions of Icer

The influence of the Institute for Clinical and Economic Review (ICER) value assessment framework (VAF) on payer decisions has been increasing in recent years. There is limited evidence assessing how ICER’s VAF updates have influenced perceptions ICER reports over time. To assess trends evaluations last 4 Double-blinded web-based surveys were fielded November 2016, 2018, October 2020 to individuals from integrated health delivery systems, pharmacy benefits managers, managed care organizations, specialty pharmacies. 55, 54, 47 payers who completed 2020, respectively. Respondents identified clinical outcomes relevant decision making (62%), validity (57%), clear transparent methodology (53%) as top strengths 2020. In prior years, a (53% 2016 56% 2018) was considered strength. Limitations somewhat consistent with including not having results at time (30% vs 28% 2018 45% 2016). comparative effectiveness (79%) health-benefit price benchmarks (57%) most influential components which especially (100% 89% 2018). unclear component steadily other contextual considerations section 37% 27% While evolved, transparency consistently reported strength time, timeliness continues be primary limitation.